ClinicalTrials.Veeva

Menu

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Enrolling
Phase 2
Phase 1

Conditions

Advanced Solid Tumors

Treatments

Drug: Nivolumab
Drug: BMS-986449

Study type

Interventional

Funder types

Industry

Identifiers

NCT05888831
U1111-1287-3575 (Registry Identifier)
2023-503484-42 (EudraCT Number)
CA120-1001

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy (measurable by Response Evaluation Criteria in Solid Tumors [RECIST] v1.1), and have received, be refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant.

    • Part 1A may have a solid malignancy of any histology.
    • Part 1B is restricted to participants with Non-small cell lung cancer (NSCLC).
    • Part 1C is restricted to participants with Triple-negative breast cancer (TNBC).
  • Tumor biopsy must be obtained for all participants (unless medically precluded).

Exclusion criteria

  • History of Grade ≥ 3 toxicity related to prior T-cell agonist or checkpoint inhibitor therapy (eg, anti-cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], or anti-PD- 1/programmed death-ligand 1 [PD-L1] treatment, or any other antibody or drug specifically targeting T-cell co-stimulation or other immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures.
  • Current or recent (within 3 months of study intervention administration) gastrointestinal disease or gastrointestinal surgery (eg, intestinal/gastric/colon resection) that could impact the absorption of study intervention.
  • Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.

Other protocol-defined criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

100 participants in 3 patient groups

Dose Escalation: BMS-986449 monotherapy
Experimental group
Treatment:
Drug: BMS-986449
Dose Escalation: BMS-986449 + nivolumab
Experimental group
Treatment:
Drug: BMS-986449
Drug: Nivolumab
Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts
Experimental group
Treatment:
Drug: BMS-986449

Trial contacts and locations

22

Loading...

Central trial contact

BMS Study Connect Contact Center www.BMSStudyConnect.com; First line of the email MUST contain the NCT# and Site #.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems